QuellTX Logo

News

08/04/20

Quell Therapeutics Enters a Collaborative Research Agreement with the Hannover Medical School

Collaboration will accelerate Quell’s pipeline expansion into autoimmune and inflammatory diseases London and Hannover – April 7 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a…...

Read More
24/02/20

T regs are back – promising to do for autoimmunity what CAR Ts have done in cancer

The following article was published in BioCentury Drug developers are giving regulatory T cells a second look as treatments for autoimmune disease. The difference this time is that they can leverage orthogonal benefits from CAR T cells in cancer, capitalizing on new…...

Read More
23/09/19

Quell Therapeutics named a “Fierce 15“ Company by FierceBiotech

London, 23 September 2019 – Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private…...

Read More
13/06/19

Quell Therapeutics, founded by Syncona Ltd, appoints Chief Executive

Building a team of leading experts in the field of Regulatory T cell-based therapy and biology London, 13 June 2019 – Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces the appointment of Iain McGill,…...

Read More